Utah Medical Products, Inc.
58.53-0.70 (-1.18%)
Oct 28, 4:00:00 PM EDT · NasdaqGS · UTMD · USD
Key Stats
Market Cap
187.54MP/E (TTM)
16.53Basic EPS (TTM)
3.54Dividend Yield
0.02%Recent Filings
8-K
Q3 revenues dip 2% on cancellations
Utah Medical Products reported Q3 2025 revenues down 2% to $9.8M and 9M sales off 7% to $29.5M, hit hard by a China distributor's cancellation of non-cancellable orders, costing $581K in revenue and a $395K bad debt reserve. Operating income plunged 22% in Q3 amid lower absorption and higher expenses, yet share repurchases cushioned EPS decline to 20%. Tariffs jacked up costs; full-year sales now eyed 7% below 2024.
10-Q
Q2 FY2025 results
Utah Medical Products posted Q2 FY2025 sales of $9.95M, down 4.3% y/y but up 6.7% q/q (derived), as PendoTECH OEM demand eased while direct U.S. sales climbed 10% y/y. Gross margins slipped to 56.2% from 60.1% y/y, hit by Ireland's product mix and lower volumes, yet operating income held at $3.20M (32.1% margin) thanks to $355K less litigation spend. Diluted EPS of $0.94 edged down 4.0% y/y, cushioned by share buybacks shrinking diluted shares to 3.25M from 3.53M; YTD EPS of $1.86 reconciles fully with no anti-dilution. Cash stayed rock-solid at $82.2M with zero debt, funding $6.7M repurchases and $2.0M dividends amid $7.3M operating cash flow. Non-GAAP EBITDA not disclosed in the 10-Q. Shares repurchased. Tariff threats loom over OUS distributor orders.
8-K
Q2 revenues dip 4.3%
Utah Medical Products reported Q2 2025 revenues of $9.953 million, down 4.3% from $10.4 million in Q2 2024, driven by a 61.7% drop in sales to OEM customer PendoTECH, though offset by 10% growth in direct domestic device sales and 8% in U.S. Filshie Clip System. Gross margins slipped to 56.2% from 60.1% due to unfavorable mix in Ireland operations and lower volumes absorbing fixed costs, while operating income fell 7.1% to $3.196 million amid $355 lower litigation expenses. Net income declined 11.7% to $3.048 million, with EPS at $0.939 after buybacks reduced shares. Balance sheet stays debt-free with $82.2 million in cash; PendoTECH sales expected $2 million lower for full-year 2025.
10-Q
Q1 FY2025 results
Utah Medical Products kicked off 2025 with net sales of $9.7M, down 14.4% year-over-year from $11.3M, mainly from a $1.5M drop in OEM sales to PendoTECH that hit 91% of the decline; excluding that, domestic sales rose 9% while outside-US sales fell 14%. Gross profit slid to $5.5M with a 57.0% margin, off from 59.7%, as fixed overheads weighed heavier on lower volumes, yet operating income held at $3.2M (32.5% margin) thanks to $0.5M less in litigation costs. Net income landed at $3.0M or $0.92 diluted EPS, 23.1% below last year but cushioned by 8.5% fewer shares from repurchases. Cash swelled to $83.3M on $4.5M operating inflows minus $0.2M capex, yielding $4.3M free cash flow, with no debt and a rock-solid balance sheet. Stock buybacks continue apace. Filshie clip lawsuits linger as a key risk.
8-K
Stockholders elect director amid withholds
Utah Medical Products stockholders elected Carrie Leigh to the board on May 2, 2025, despite 1.76 million withheld votes, with the board rejecting her conditional resignation to uphold her three-year term. They ratified Haynie & Co. as auditors for 2025 with overwhelming support and approved executive compensation on an advisory basis. Yet votes reveal governance tensions. Annual say-on-pay votes persist.
IPO
Website
Employees
Sector
Industry
BFLY
Butterfly Network, Inc.
2.21+0.01
CNMD
CONMED Corporation
47.32-0.04
ICUI
ICU Medical, Inc.
120.11-2.80
MASI
Masimo Corporation
146.41-1.59
MDT
Medtronic plc.
93.23-0.90
MHUA
Meihua International Medical Te
0.26+0.01
MMSI
Merit Medical Systems, Inc.
82.79+0.04
RMD
ResMed Inc.
256.57-2.64
UEEC
United Health Products, Inc.
0.08+0.00
UFPT
UFP Technologies, Inc.
197.89-2.12